Pfizer has introduced its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 serotypes responsible for the majority of invasive and non-invasive pneumococcal diseases. The vaccine aims to provide timely, proactive protection for all adults, including those with chronic health conditions.

Key highlights

Broad-spectrum protection

• Targets 20 pneumococcal serotypes linked to serious infections.

• Designed for adults, including those with chronic conditions such as asthma, COPD, chronic kidney disease, and diabetes.

Advanced vaccine technology

• Utilizes conjugation technology combining a weak antigen with a strong protein carrier.

• Generates stronger, longer-lasting immunity and immunological memory through T-cell dependent immune responses.

High-risk population focus
Adults over 50 and individuals with comorbidities face increased risk of complications, hospitalization, and mortality from pneumococcal infections.

Pfizer’s preventive health commitment

• Builds on 25 years of leadership in pneumococcal vaccine innovation.

• Reinforces focus on adult immunization and preventive healthcare in India.

Statements from Leaders
"Adults over 50 years and those with chronic conditions are at a significantly higher risk of pneumococcal infections. With PCV20, we aim to enable timely and proactive protection, preventing complications and saving lives," said Meenakshi Nevatia, MD, Pfizer India.

The launch of PCV20 could play a pivotal role in expanding adult vaccination coverage in India, especially for high-risk groups, and marks another milestone in Pfizer’s global immunization strategy.